These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38493007)

  • 1. Revolutionising healing: Gene Editing's breakthrough against sickle cell disease.
    Dimitrievska M; Bansal D; Vitale M; Strouboulis J; Miccio A; Nicolaides KH; El Hoss S; Shangaris P; Jacków-Malinowska J
    Blood Rev; 2024 May; 65():101185. PubMed ID: 38493007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
    Paschoudi K; Yannaki E; Psatha N
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34
    Katta V; O'Keefe K; Li Y; Mayuranathan T; Lazzarotto CR; Wood RK; Levine RM; Powers A; Mayberry K; Manquen G; Yao Y; Zhang J; Jang Y; Nimmagadda N; Dempsey EA; Lee G; Uchida N; Cheng Y; Fazio F; Lockey T; Meagher M; Sharma A; Tisdale JF; Zhou S; Yen JS; Weiss MJ; Tsai SQ
    Mol Ther; 2024 Oct; 32(10):3433-3452. PubMed ID: 39086133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 gene editing for curing sickle cell disease.
    Park SH; Bao G
    Transfus Apher Sci; 2021 Feb; 60(1):103060. PubMed ID: 33455878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9-based gene-editing technology for sickle cell disease.
    Ma L; Yang S; Peng Q; Zhang J; Zhang J
    Gene; 2023 Jul; 874():147480. PubMed ID: 37182559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo HSC prime editing rescues sickle cell disease in a mouse model.
    Li C; Georgakopoulou A; Newby GA; Chen PJ; Everette KA; Paschoudi K; Vlachaki E; Gil S; Anderson AK; Koob T; Huang L; Wang H; Kiem HP; Liu DR; Yannaki E; Lieber A
    Blood; 2023 Apr; 141(17):2085-2099. PubMed ID: 36800642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
    Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
    Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges.
    Demirci S; Leonard A; Haro-Mora JJ; Uchida N; Tisdale JF
    Adv Exp Med Biol; 2019; 1144():37-52. PubMed ID: 30715679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
    Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
    N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
    Magrin E; Miccio A; Cavazzana M
    Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.
    Métais JY; Doerfler PA; Mayuranathan T; Bauer DE; Fowler SC; Hsieh MM; Katta V; Keriwala S; Lazzarotto CR; Luk K; Neel MD; Perry SS; Peters ST; Porter SN; Ryu BY; Sharma A; Shea D; Tisdale JF; Uchida N; Wolfe SA; Woodard KJ; Wu Y; Yao Y; Zeng J; Pruett-Miller S; Tsai SQ; Weiss MJ
    Blood Adv; 2019 Nov; 3(21):3379-3392. PubMed ID: 31698466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies.
    Li C; Georgakopoulou A; Newby GA; Everette KA; Nizamis E; Paschoudi K; Vlachaki E; Gil S; Anderson AK; Koob T; Huang L; Wang H; Kiem HP; Liu DR; Yannaki E; Lieber A
    JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36006707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
    Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
    Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells.
    DeWitt MA; Magis W; Bray NL; Wang T; Berman JR; Urbinati F; Heo SJ; Mitros T; Muñoz DP; Boffelli D; Kohn DB; Walters MC; Carroll D; Martin DI; Corn JE
    Sci Transl Med; 2016 Oct; 8(360):360ra134. PubMed ID: 27733558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly efficient therapeutic gene editing of human hematopoietic stem cells.
    Wu Y; Zeng J; Roscoe BP; Liu P; Yao Q; Lazzarotto CR; Clement K; Cole MA; Luk K; Baricordi C; Shen AH; Ren C; Esrick EB; Manis JP; Dorfman DM; Williams DA; Biffi A; Brugnara C; Biasco L; Brendel C; Pinello L; Tsai SQ; Wolfe SA; Bauer DE
    Nat Med; 2019 May; 25(5):776-783. PubMed ID: 30911135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34
    Lamsfus-Calle A; Daniel-Moreno A; Antony JS; Epting T; Heumos L; Baskaran P; Admard J; Casadei N; Latifi N; Siegmund DM; Kormann MSD; Handgretinger R; Mezger M
    Sci Rep; 2020 Jun; 10(1):10133. PubMed ID: 32576837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus.
    Antoniani C; Meneghini V; Lattanzi A; Felix T; Romano O; Magrin E; Weber L; Pavani G; El Hoss S; Kurita R; Nakamura Y; Cradick TJ; Lundberg AS; Porteus M; Amendola M; El Nemer W; Cavazzana M; Mavilio F; Miccio A
    Blood; 2018 Apr; 131(17):1960-1973. PubMed ID: 29519807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
    Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome editing approaches to β-hemoglobinopathies.
    Brusson M; Miccio A
    Prog Mol Biol Transl Sci; 2021; 182():153-183. PubMed ID: 34175041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
    Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
    Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.